Find us on:

2019 is already breaking records when it comes to Low Dose Naltrexone (LDN) research, with more data and articles published this year than any previous first quarter. Growing awareness of LDN has positively impacted the investigation and discovery of new uses for the drug as well as resulted in additional articles being published about existing conditions.

Check out the latest 2019 articles below about the use of LDN for pain, chronic illness, and skin disorders, as well as a review article confirming the safety of this versatile medication.

LDN Publication by Year

Landing Page: LDN 2019 Q1

LDN for Pain Management

Low Dose Naltrexone for Neuropathic Pain Related to an Electrical Burn Injury: A Case Study
A 36-year old man sustained an electrical burn injury causing chronic burning and tingling of his left hand and flank. Despite surgery and the use of multiple medications, the pain continued until he was prescribed LDN. Within 8 weeks of being on LDN, his pain decreased significantly.

Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes
This paper discusses LDN’s effectiveness and mechanism of action in alleviating pain unrelated to cancer and enhancing quality of life in the palliative care setting.

Low Dose Naltrexone: A Viable Alternative for Long Term Chronic Pain?
This case report highlights a chronic pain patient who was able to wean down from a high dose opioid regimen by using low dose naltrexone.

Treating chronic pain with low dose naltrexone and ultralow dose naltrexone: a review paper.
In this review paper from the University of Kansas School of Medicine, LDN is evaluated for treating chronic pain due to its ability to decrease inflammation.

The Use of Low-Dose Naltrexone for Chronic Pain
This review article from Mercer University discusses the effectiveness of LDN in treating chronic pain with minimal side effects, no drug-drug interactions, and at a low cost.

Landing Page: LDN 2019 Q1

LDN for Chronic Disease / Autoimmune Disease

Low-Dose Naltrexone in the Treatment of Fibromyalgia: A Retrospective Analysis
This is a planned retrospective study in Wisconsin looking at the effectiveness of LDN in managing fibromyalgia given the complex nature of the disease and limited viable treatment options.

Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy
Sjogren’s Syndrome is a chronic autoimmune disorder that causes the inflammation of the tear ducts and salivary glands, resulting in dryness of the eyes and mouth. This report describes a case of a 47-year-old woman with suspected Sjogren's who failed standard therapy but improved clinically with LDN.

Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study
The results of this study support the hypothesis that persistent use of LDN reduces the need for medication used in the treatment of rheumatic and seropositive arthritis.



Landing Page: LDN 2019 Q1

LDN for Dermatologic Problems

The use of naltrexone in dermatology. Current evidence and future directions
The authors discuss how LDN, a low cost, and well-tolerated medication, modulates the immune system and decreases inflammation in various skin disorders such as familial benign chronic pemphigus (Hailey-Hailey disease), dermatomyositis, systemic sclerosis, psoriasis, and lichen planopilaris.

Low Dose Naltrexone in Dermatology
In this article, the authors examine the evidence for the use of of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis.

Variable response to low-dose naltrexone in patients with Darier disease: a case series
Darier disease is characterized by red-brown bumps on the skin with very limited treatment options. This study reports the successful use of LDN for patients with mild to moderate forms of the disease.

Low-dose Naltrexone: An Alternative Treatment for Erythrodermic Psoriasis
A patient with psoriasis was treated with 4.5 mg of LDN for 6 months after a flare-up. There was a significant improvement in her flare-up and she achieved remission after only three months of treatment.



Landing Page: LDN 2019 Q1

The Safety of LDN

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.
This paper reviewed 89 clinical trials with 11,194 participants with various medical conditions and found that LDN does not appear to increase the risk of serious side effects over placebo.